Arpana Edala, MD
Internal Medicine · Little Rock, ARNPI 1265662969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $20.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$673
- Otsuka America Pharmaceutical, Inc.$639
- Novartis$637
- Bayer$477
- Acadia Pharmaceuticals Inc$357
- Sunovion Pharmaceuticals Inc.$346
- plus $3K from 33 others
What the payments were for
- Food & beverage$5,93498%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $673 |
| Otsuka America Pharmaceutical, Inc. | 23 | $639 |
| Novartis | 38 | $637 |
| Bayer | 23 | $477 |
| Acadia Pharmaceuticals Inc | 17 | $357 |
| Sunovion Pharmaceuticals Inc. | 18 | $346 |
| Lundbeck LLC | 20 | $319 |
| Johnson & Johnson | 9 | $302 |
| Pfizer | 14 | $298 |
| Teva Pharmaceuticals USA, Inc. | 10 | $268 |
| Eisai Inc. | 5 | $211 |
| Lilly USA, LLC | 13 | $206 |
| Avanir Pharmaceuticals, Inc. | 11 | $177 |
| Idorsia Pharmaceuticals US Inc | 6 | $129 |
| Biogen | 6 | $99 |
| Genentech USA, Inc. | 1 | $92 |
| Neurocrine Biosciences, Inc. | 4 | $92 |
| Amarin Pharma, Inc. | 5 | $78 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Sun Pharmaceutical Industries Inc. | 3 | $59 |
| Corium, LLC | 4 | $50 |
| UCB, Inc. | 3 | $47 |
| AstraZeneca | 3 | $41 |
| Urovant Sciences Inc | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $32 |
| Novo Nordisk | 2 | $32 |
| Scilex Pharmaceuticals Inc. | 2 | $30 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Boston Scientific | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Abbott | 1 | $19 |
| Merck | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| GSK | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Exact Sciences | 1 | $14 |
| CMP Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,046 in reported general payments places this provider in the 90th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,050 | $311,022 |
| XareltoRivaroxaban | 194 | $58,785 |
| EntrestoSacubitril/Valsartan | 157 | $51,971 |
| MyrbetriqMirabegron | 160 | $45,146 |
| Memantine Hcl | 723 | $43,687 |
| OzempicSemaglutide | 40 | $41,611 |
| TresibaInsulin Degludec | 46 | $32,400 |
| GemtesaVibegron | 129 | $31,373 |
| JanuviaSitagliptin Phosphate | 73 | $29,497 |
| FingolimodFingolimod Hcl | 12 | $25,084 |
| Potassium Chloride | 1,013 | $23,616 |
| Atorvastatin Calcium | 1,303 | $20,111 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 68 | $20,002 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $19,128 |
| Divalproex Sodium | 501 | $18,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $298 | $316,7531,062 claims |
| Novo NordiskOzempic, Tresiba | $32 | $74,01186 claims |
| Johnson & JohnsonXarelto | $302 | $58,785194 claims |
| NovartisEntresto | $637 | $51,971157 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $45,146160 claims |
| MerckJanuvia, Lagevrio (Eua) | $19 | $40,56385 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $18 | $33,38261 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $35 | $31,373129 claims |
| Lilly USA, LLCTrulicity | $206 | $14,63218 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Little Rock
- Aaron StrobelLittle Rock$32K
- Jeremy DavisLittle Rock$17K
- Ritesh RampureLittle Rock$13K
- Milton RoachLittle Rock$12K
- Michael CloudLittle Rock$10K
- Saul Rios HerreraLittle Rock$8K
- Zhangning ChenLittle Rock$8K
- Russell RoarkLittle Rock$7K
- Srikanth VallurupalliLittle Rock$5K
- Devendra PatelLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.